Claims for Patent: 6,355,245

Summary for Patent: 6,355,245

Title:	C5-specific antibodies for the treatment of inflammatory diseases
Abstract:	The use of anti-C5 antibodies, e.g., monoclonal antibodies, to treat glomerulonephritis (GN) is disclosed. The administration of such antibodies at low dosage levels has been found to significantly reduce glomerular inflammation/enlargement and other pathologic conditions associated with GN. Also disclosed are anti-C5 antibodies and anti-C5 antibody-encoding nucleic acid molecules. These antibodies are useful in the treatment of GN and other inflammatory conditions involving pathologic activation of the complement system.
Inventor(s):	Evans; Mark J. (Cheshire, CT), Matis; Louis A. (Southport, CT), Mueller; Eileen Elliott (East Haven, CT), Nye; Steven H. (Mequon, WI), Rollins; Scott (Monroe, CT), Rother; Russell P. (Cheshire, CT), Springhorn; Jeremy P. (Cheshire, CT), Squinto; Stephen P. (Bethany, CT), Thomas; Thomas C. (Madison, CT), Wilkins; James A. (Woodbridge, CT)
Assignee:	Alexion Pharmaceuticals, Inc. (Cheshire, CT)
Application Number:	08/487,283
Patent Claims:	1. An antibody comprising at least one antibody-antigen binding site, said antibody exhibiting specific binding to human complement component C5, said specific binding being targeted to the alpha chain of human complement component C5, wherein the antibody 1) inhibits complement activation in a human body fluid, 2) inhibits the binding of purified human complement component C5 to either human complement component C3 or human complement component C4, and 3) does not specifically bind to the human complement activation product free C5a. 2. The antibody of claim 1 wherein the inhibition of complement activation in the human body fluid is measurable as an increment of blockade of C5a generation and an increment of blockade of complement hemolytic activity in the body fluid, said increment of blockade of C5a generation being substantially equal to said increment of blockade of complement hemolytic activity. 3. The antibody of claim 1 wherein, upon binding to human C5, there is a 60% to 90% reduction in the ability of C5 to bind to human complement component C3. 4. The antibody of claim 1 wherein, upon binding to human C5, there is a 60% to 90% reduction in the ability of C5 to bind to human complement component C4. 5. The antibody of claim 1 wherein the antibody binds specifically to an isolated oligopeptide comprising an amino acid sequence corresponding to amino acid 8 through amino acid 12 of SEQ ID NO:1. 6. The antibody of claim 1 wherein the inhibition of complement activation in the human body fluid is measurable as a substantially complete blockade of C5a generation in the body fluid and a substantially complete blockade of complement hemolytic activity in the body fluid when the antibody is added to the body fluid at a concentration yielding a ratio equal to or less than 10 moles of antibody-antigen binding sites of the antibody to 1 mole of human C5 in the body fluid. 7. The antibody of claim 1 wherein the antibody is a humanized antibody. 8. The antibody of claim 1 wherein the antibody is an scFv. 9. The antibody of claim 1, wherein, when administered to a human patient via intravenous infusion, the antibody provides complete complement inhibition at dosages below 0.005 g/kg. 10. The antibody of claim 1, wherein, when administered to a human patient via intravenous infusion, the antibody provides therapeutic benefits at dosages below 0.0022 g/kg. 11. The antibody of claim 10, wherein the antibody is administered in association with an extracorporeal circulation procedure. 12. The antibody of claim 1 wherein the inhibition of complement activation in the human body fluid is measurable as a substantially complete blockade of C5a generation in the body fluid and a substantially complete blockade of complement hemolytic activity in the body fluid when the antibody is added to the body fluid at a concentration yielding a ratio equal to or less than 3 moles of antibody-antigen binding sites of the antibody to 1 mole of human C5 in the body fluid. 13. The antibody of claim 1, wherein, when administered to a human patient via intravenous infusion, the antibody provides therapeutically effective complement inhibition at dosages below 0.003 g/kg. 14. A sterile non-pyrogenic therapeutic agent comprising the antibody of claim 1 in a formulation suitable for administration to a human. 15. The therapeutic agent of claim 14 wherein the antibody is a humanized immunoglobulin. 16. The therapeutic agent of claim 14 wherein the antibody is an scFv. 17. The therapeutic agent of claim 14 wherein the antibody is made up of two or more heterodimeric subunits each containing one heavy and one light chain. 18. Antibody 5G1.1 scFv CB (humanized) having the amino acid sequence encoded by the nucleic acid sequence of SEQ ID NO:8. 19. An isolated antigen binding protein comprising: 1) a variable light region CDR1 comprising an amino acid sequence corresponding to amino acid residues 26-36 of SEQ ID NO:8, 2) a variable light region CDR2 comprising an amino acid sequence corresponding to amino acid residues 52-58 of SEQ ID NO:8, 3) a variable light region CDR3 comprising an amino acid sequence corresponding to amino acid residues 91 through amino acid 99 of SEQ ID NO:8, 4) a variable heavy region CDR1 comprising an amino acid sequence corresponding to amino acid residues 152 through amino acid 161 of SEQ ID NO:8, 5) a variable heavy region CDR2 comprising an amino acid sequence corresponding to amino acid residues 176 through amino acid 192 of SEQ ID NO:8, 6) a variable heavy region CDR3 comprising an amino acid sequence corresponding to amino acid residues 225 through amino acid 237 of SEQ ID NO:8, said protein exhibiting specific binding to human complement component C5, said specific binding being targeted to the alpha chain of human complement component C5, wherein the protein inhibits complement activation in a human body fluid and does not specifically bind to the human complement activation product free C5a. 20. A nucleic acid molecule comprising a nucleotide sequence encoding a polypeptide comprising a variable heavy chain region amino acid sequence corresponding to amino acid 1 through amino acid 122 of SEQ ID NO: 12. 21. Hybridoma 5G1.1 having ATCC designation HB-11625. 22. An antibody produced by the hybridoma of claim 21. 23. An antibody comprising at least one antibody-antigen binding site, said antibody exhibiting specific binding to human complement component C5, said specific binding being targeted to the alpha chain of human complement component C5, wherein: (A) the antibody inhibits (i) C5b-9-mediated hemolysis and (ii) C5a generation in a fluid comprising human serum; and (B) the antibody does not specifically bind to the human complement activation product free C5a.

Details for Patent 6,355,245

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Alexion Pharmaceuticals, Inc.	SOLIRIS	eculizumab	Injection	125166	03/16/2007		2019-03-12

International Patent Family for US Patent 6,355,245

Country	Patent Number	Estimated Expiration
Austria	448791
Australia	2474795
Brazil	9507594